ACRV1

Across TCGA pan-cancer cohorts, ACRV1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACRV1 data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACRV1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACRV1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ACRV1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.665	0.919	.001	56	view →
HNSC	OS	Tertile	All	0.753	0.930	.002	36	view →
LUAD	OS	Tertile	II,III,IV	0.902	0.384	.002	14	view →
LSCC	OS	Quartile	III,IV	0.516	0.925	.026	9	view →
CCRCC	OS	Tertile	All	0.536	0.939	.022	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACRV1–PDAC (DFS)

Open the PDAC breakdown →